Letermovir Injection

Contraindicated

Letermovir Injection Bromocriptine Cycloset Increased ergot alkaloids exposure and an increased risk of ergotism Details Letermovir Injection Dihydroergotamine Brekiya Increased ergot alkaloids exposure and an increased risk of ergotism Details Letermovir Injection Ergotamine Ergomar Increased ergot alkaloids exposure and an increased risk of ergotism Details Letermovir Injection Flibanserin Addyi Increased flibanserin exposure and an increased flibanserin-related adverse effects Details Letermovir Injection Lomitapide Increased lomitapide exposure Details Letermovir Injection Pimozide Increased pimozide exposure and an increased risk for QT prolongation and torsades de pointes Details

Major

Letermovir Injection Abiraterone Acetate Abirtega Increased CYP3A substrate exposure Details Letermovir Injection Abiraterone Acetate, Micronized Abirtega Increased CYP3A substrate exposure Details Letermovir Injection Acalabrutinib Calquence Increased acalabrutinib exposure and increased risk of toxicity Details Letermovir Injection Alfentanil Increased CYP3A substrate exposure Details Letermovir Injection Alfuzosin UroXatral Increased CYP3A substrate exposure Details Letermovir Injection Alprazolam Xanax Increased ALPRAZolam exposure and an increased risk of ALPRAZolam-related adverse reactions Details Letermovir Injection Amiodarone Nexterone Increased amiodarone exposure Details Letermovir Injection Amlodipine Amvaz® Increased amLODIPine exposure and an increased risk of hypotension and edema Details Letermovir Injection Amprenavir Increased CYP3A substrate exposure Details Letermovir Injection Apalutamide Erleada Reduced letermovir exposure and reduced efficacy of letermovir Details Letermovir Injection Apixaban Eliquis Increased CYP3A substrate exposure Details Letermovir Injection Aprepitant Aponvie Increased aprepitant exposure Details Letermovir Injection Aripiprazole Abilify Increased CYP3A substrate exposure Details Letermovir Injection Artemether Increased CYP3A substrate exposure Details Letermovir Injection Astemizole Increased CYP3A substrate exposure Details Letermovir Injection Atazanavir Reyataz Increased CYP3A substrate exposure Details Letermovir Injection Atogepant Qulipta Increased atogepant exposure Details Letermovir Injection Atorvastatin Atorvaliq Increased atorvastatin exposure and an increased risk for myopathy and rhabdomyolysis Details Letermovir Injection Atrasentan Increased atrasentan exposure and an increased risk of atrasentan-related adverse reactions Details Letermovir Injection Avacopan Tavneos Increased CYP3A substrate exposure Details Letermovir Injection Avapritinib Ayvakit Increased avapritinib exposure and an increased risk of the incidence and severity of adverse reactions Details Letermovir Injection Avatrombopag Doptelet Increased CYP3A substrate exposure Details Letermovir Injection Axitinib Inlyta Increased CYP3A substrate exposure Details Letermovir Injection Bedaquiline Sirturo Increased bedaquiline exposure Details Letermovir Injection Belumosudil Rezurock Increased CYP3A substrate exposure Details Letermovir Injection Benzhydrocodone Increased HYDROcodone exposure and risk of increased or prolonged opioid effects Details Letermovir Injection Berotralstat Orladeyo Increased P-gp substrate exposure Details Letermovir Injection Bictegravir Increased CYP3A substrate exposure Details Letermovir Injection Boceprevir Increased CYP3A substrate exposure Details Letermovir Injection Bosentan Increased bosentan exposure, reduced letermovir exposure and reduced efficacy of letermovir Details Letermovir Injection Bosutinib Bosulif Increased bosutinib exposure Details Letermovir Injection Brexpiprazole Rexulti Increased brexpiprazole exposure Details Letermovir Injection Brigatinib Alunbrig Increased brigatinib exposure Details Letermovir Injection Budesonide Entocort Increased budesonide exposure Details